ALP bouncing and LDH normalization in bone metastatic castration-resistant prostate cancer patients under therapy with Enzalutamide: an exploratory analysis.

Schlack, Katrin; Krabbe, Laura-Maria; Rahbar, Kambiz; Isenberg, Karoline; Semjonow, Axel; Schrader, Andres Jan; Boegemann, Martin

Schlack, Katrin; Krabbe, Laura-Maria; Rahbar, Kambiz; Isenberg, Karoline; Semjonow, Axel; Schrader, Andres Jan; Boegemann, Martin.

Afiliação

Schlack K; Department of Urology, Prostate Center, University of Muenster Medical Center, Muenster, Germany.
Krabbe LM; Department of Urology, Prostate Center, University of Muenster Medical Center, Muenster, Germany.
Rahbar K; Department of Nuclear Medicine, University of Muenster Medical Center, Muenster, Germany.
Isenberg K; Department of Urology, Prostate Center, University of Muenster Medical Center, Muenster, Germany.
Semjonow A; Department of Urology, Prostate Center, University of Muenster Medical Center, Muenster, Germany.
Schrader AJ; Department of Urology, Prostate Center, University of Muenster Medical Center, Muenster, Germany.
Boegemann M; Department of Urology, Prostate Center, University of Muenster Medical Center, Muenster, Germany.

Transl Androl Urol ; 10(10): 3986-3999, 2021 Oct.

Article em En | MEDLINE | ID: mdl-34804841

Palavras-chave

Alkaline phosphatase (ALP); Enzalutamide; bone metastatic castration-resistant prostate cancer (bmCRPC); lactate dehydrogenase (LDH); prostate-specific antigen (PSA)

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Transl Androl Urol Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google